Long- and short-acting β2-adrenergic agonists: Effects on airway function in patients with asthma

Archives of Internal Medicine

Volumn 156, Issue 14, 1996, Pages 1514-1520

  Busse, William W ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL; SALMETEROL;

ASTHMA; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHOCONSTRICTION; HUMANS; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM;

EID: 0030054983     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.14.1514     Document Type: Review

References (63)

1. Inman WHN, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols. Lancet. 1969;2:279-283.
2. Speizer FE, Doll R, Heaf P, Strang LB. Investigation into use of drugs preceding death from asthma. BMJ. 1968;1:339-343.
3. Paterson JW, Conolly ME, Davies DS, Dollery CT. Isoprenaline resistance and the use of pressurized aerosols in asthma. Lancet. 1968;2:426-429.
4. Reisman RE. Asthma induced by adrenergic aerosols. J Allergy. 1970;46:162-170.
5. Jackson RT, Beaglehole R, Rea HH, Sutherland DC. Mortality from asthma: a new epidemic in New Zealand. BMJ. 1982;285:771-774.
6. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336:1391-1396.
7. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrest in young asthmatics on salmeterol. Respir Med. 1993;87:227-228.
8. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-1037.
9. Mann RD. Results of prescription event monitoring study of salmeterol. BMJ. 1994;309:1018.
10. Finkelstein FN. Risks of salmeterol? N Engl J Med. 1994;331:1314.
11. Crane J, Burgess C, Pearce N, Beasely R. The β-agonist controversy: a perspective. Eur Respir Rev. 1993;3:475-482.
12. National Asthma Education Program, Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health; 1991. US Dept of Health and Human Services publication PHS 91-3042.
13. Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. Respiratory arrest in near-fatal asthma. N Engl J Med. 1991;324:285-288.
14. 2-agonists in the management of asthma. Drug Safety. 1992;7:54-70.
15. National Institutes of Health. Global Initiative for Asthma. Bethesda, Md: National Institutes of Health; 1995. US Dept of Health and Human Services publication 95-3659.
16. Lemanske RF, Joad J. Beta-2 receptor agonists in asthma: a comparison. J Asthma. 1990;27: 101-109.
17. Physician's Desk Reference. 49th ed. Montvale, NJ: Medical Economics Data Production Co; 1995.
18. National Heart, Lung, and Blood Institute, International Consensus Report on Diagnosis and Treatment of Asthma. Bethesda, Md: National Heart, Lung and Blood Institute; 1992. Publication NIH 92-3091.
19. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroids on airway hyperresponsiveness and clinical asthma in nonsteroids-dependent asthmatics. Am Rev Respir Dis. 1990;142:632-636.
20. Kerrebijn KF, Van Ess-Zandvliet EM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79:653-659.
21. 2-agonist. Ann Pharmacother. 1993;27:1478-1487.
22. 2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988;43:674-678.
23. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four-week study of a long-acting beta-adrenoceptor agonist for tne treatment of reversible airways disease. Eur Respir J. 1991;4:1178-1184.
24. Ullman A, Bergendal A, Linden A, Waldeck B, Skoogh BE, Lofdahl CG. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea pig trachea with or without epithelium. Allergy. 1992; 47:384-387.
25. Beach JR, Young CL, Stenton C, Avery AJ, Wahers EH, Hendrick DJ. A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol. 1992;5:133-135.
26. Anderson SD, Rodwell LT, DuToit J, Young IH. Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest. 1991;100:1254-1261.
27. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327:1420-1425.
28. Kemp JP, Dockhorn RJ, Busse WW, Blecker ER, Vanas A. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med. 1994;150:1612-1615.
29. Greening AP, Wind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
30. Van Schayck CP, Visch MB, van Herwaarden CLA, et al. Increased bronchial hyperresponsiveness after inhaling salbutamol during one year is not caused by desensitization to salbutamol. J Allergy Clin Immunol. 1990;86:793-800.
31. Repsher LH, Anderson JA, Bush RK. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest. 1984;85:34-38.
32. 2-agonist treatment. Am Rev Respir Dis. 1993;148:707-712.
33. Harvey JE, Tattersfield AE. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, and atopic, and asthmatic subjects. Thorax. 1982;37:280-287.
34. Gibson GJ, Greenacre JK, Konig P, Conolly ME, Pride NB. Use of exercise challenge to investigate possible tolerance to β-adrenoceptor stimulation in asthma. Br J Dis Chest. 1978;72:199-206.
35. Kraan J, Koeter GH, van der Mark TW, Sluiter MJ, deVries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985;76:628-636.
36. 2-agonists in asthma. Ann Allergy. 1992;69:381-384.
37. 2-agonists: implications for drug therapy. Drugs. 1994;47:207-222.
38. Schuster A, Kizlik R, Reinhardt D. Influence of short- and long-term inhalation of salbutamol on lung function and β2-adrenoceptors of mononuclear blood cells in asthmatic children. Eur J Pediatr. 1991;150:209-213.
39. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989;140:586-592.
40. Lipworth BJ, Clark RA, Dhillon DP, McDevitt DG. Subsensitivity of β-adrenoceptor responses in asthmatic patients taking regular low-dose inhaled salbutamol. Eur J Clin Pharmacol. 1990;38:203-205.
41. Brogden RN, Faulds D. Salmeterol xinofoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Allergol Immunopathol. 1992;20:72-84.
42. Bardin PG, Joubert JR. Inhaled β-stimulants: a study of hiph-dose v conventional-dose treatment in asthmatic outpatients. S Afr Med J. 1991;79:655-659.
43. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;327:1198-1203.
44. Bhagat R, Kaira S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest. 1995;108:1235-1239.
45. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. Pespir Med. 1994;8B:363-368.
46. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet. 1995;346:201-206.
47. 2-agonists in asthma. N Engl J Med. 1992;327:1204-1208.
48. Britton J, Hanley SP, Garnett HV, Hadfield JW, Tattersfield AE. Dose-related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax. 1988;43:300-305.
49. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline, Lancet. 1988;1:554-558.
50. Britton J. Tolerance to beta-agonists in asthma therapy. Lancet. 1993;342:818-819.
51. Nicklas RA. Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol. 1990;85:959-964.
52. Yarbrough J, Mansfield LE, Ting S. Metered dose inhaler induced bronchospasm in asthmatic patients. Ann Allergy. 1985;55:25-27.
53. Committee on Safety of Medicines. Curr Probl. 1991.
54. Wilkinson JRW, Roberts JA, Bradding P, Holgate ST, Howarth PH. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ. 1992;305:931-932.
55. Yarbrough J, Mansfield LE, Ting S. Immediate bronchoconstrictive response to metered dose albuterol (MD-A). Presented at the 39th Annual Congress of the American College of Allergy; January 29-February 2, 1983; New Orleans, La.
56. Finnerty JP, Howarth PH. Paradoxical broncho-constriction with nebulized albuterol but not with terbutaline. Am Rev Respir Dis. 1993;148:512-513.
57. Bryant DH, Pepys J. Bronchial reactions to aerosol inhalant vehicle. BMJ. 1976;1:1319-1320.
58. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med. 1993;87:227-228.
59. Committee on Safety of Medicines. Salmeterol. Curr Probl. 1991.
60. Lundback B, Rawlinson DW, Palmer JBD. A twelve-month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax. 1993;48:148-153.
61. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SL. Salmeterol xinofoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994; 271:1412-1416.
62. Smyth ET, Pavord ID, Wong CS, Wisniewski AF, Williams J, Tattersfield AE. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma, BMJ. 1993;306:543-545.
63. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax. 1994;49:771-774.